×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SRPT – sarepta therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SRPT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/13
10:33 pm
srpt
High Growth Tech Stocks Featuring ALSO Holding And 2 More [Yahoo! Finance]
Neutral
Report
High Growth Tech Stocks Featuring ALSO Holding And 2 More [Yahoo! Finance]
11/13
09:34 pm
srpt
High Growth Tech Stocks To Watch In The Current Market [Yahoo! Finance]
Neutral
Report
High Growth Tech Stocks To Watch In The Current Market [Yahoo! Finance]
11/13
08:30 pm
srpt
High Growth Tech Stocks To Watch This November 2024 [Yahoo! Finance]
Neutral
Report
High Growth Tech Stocks To Watch This November 2024 [Yahoo! Finance]
11/13
05:48 am
srpt
Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They Seem [Yahoo! Finance]
Low
Report
Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They Seem [Yahoo! Finance]
11/13
01:32 am
srpt
Exploring Three High Growth Tech Stocks for Your Portfolio [Yahoo! Finance]
Low
Report
Exploring Three High Growth Tech Stocks for Your Portfolio [Yahoo! Finance]
11/13
12:32 am
srpt
Exploring High Growth Tech Stocks Including Tanla Platforms And Two Others [Yahoo! Finance]
Low
Report
Exploring High Growth Tech Stocks Including Tanla Platforms And Two Others [Yahoo! Finance]
11/13
12:08 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
11/12
10:42 pm
srpt
Exploring High Growth Tech Stocks For Potential Portfolio Enhancement [Yahoo! Finance]
Low
Report
Exploring High Growth Tech Stocks For Potential Portfolio Enhancement [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2024
04:05 pm
srpt
sarepta therapeutics, inc.
BEAT
Report
-7.4%
sarepta therapeutics, inc.
8/7/2024
04:05 pm
srpt
sarepta therapeutics, inc.
BEAT
Report
7.7%
sarepta therapeutics, inc.
5/1/2024
04:05 pm
srpt
sarepta therapeutics, inc.
BEAT
Report
-1.8%
sarepta therapeutics, inc.
2/28/2024
04:05 pm
srpt
sarepta therapeutics, inc.
BEAT
Report
-8.6%
sarepta therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/13
10:28 am
srpt
Form SC 13G/A Sarepta Therapeutics, Filed by: Capital International Investors
Low
Report
Form SC 13G/A Sarepta Therapeutics, Filed by: Capital International Investors
11/6
04:02 pm
srpt
Form 10-Q Sarepta Therapeutics, For: Sep 30
High
Report
Form 10-Q Sarepta Therapeutics, For: Sep 30
9/16
08:05 pm
srpt
Form 4 Sarepta Therapeutics, For: Sep 12 Filed by: Connelly Deirdre P
Low
Report
Form 4 Sarepta Therapeutics, For: Sep 12 Filed by: Connelly Deirdre P
9/16
08:00 pm
srpt
Form 3 Sarepta Therapeutics, For: Sep 12 Filed by: Connelly Deirdre P
Low
Report
Form 3 Sarepta Therapeutics, For: Sep 12 Filed by: Connelly Deirdre P
9/16
08:52 am
srpt
Form 8-K Sarepta Therapeutics, For: Sep 12
Low
Report
Form 8-K Sarepta Therapeutics, For: Sep 12
9/5
08:01 pm
srpt
Form 4 Sarepta Therapeutics, For: Sep 04 Filed by: BEHRENS M KATHLEEN
Medium
Report
Form 4 Sarepta Therapeutics, For: Sep 04 Filed by: BEHRENS M KATHLEEN
9/3
08:00 pm
srpt
Form 4 Sarepta Therapeutics, For: Aug 30 Filed by: Estepan Ian Michael
Low
Report
Form 4 Sarepta Therapeutics, For: Aug 30 Filed by: Estepan Ian Michael
8/30
05:04 pm
srpt
Form 144 Sarepta Therapeutics, Filed by: Estepan Ian Michael
Low
Report
Form 144 Sarepta Therapeutics, Filed by: Estepan Ian Michael
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
Sarepta Therapeutics Inc (NASDAQ: SRPT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.
11.5%
2/28 Sarepta Therapeutics Inc (NASDAQ: SRPT) had its price target lowered by analysts at JPMorgan Chase & Co. from $172.00 to $160.00. They now have an "overweight" rating on the stock. 8.1%
12/23 Roche enters $1.15 bln licensing deal for Sarepta gene therapy [Reuters] 7.6%
8/8 Patient in Sarepta gene therapy trial develops serious illness; shares plunge [Reuters] 7.0%
10/31 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 6.7%
12/12 Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53 6.5%
9/10 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents at Morgan Stanley 17th Annual Global Healthcare Conference (Transcript) [Seeking Alpha] 6.3%
10/4 Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy 6.0%
11/7 Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments 4.9%
6/4 Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference 4.9%
2/28 Sarepta Therapeutics Inc (NASDAQ: SRPT) had its price target lowered by analysts at JPMorgan Chase & Co. from $172.00 to $160.00. They now have an "overweight" rating on the stock. 8.1%
12/23 Roche enters $1.15 bln licensing deal for Sarepta gene therapy [Reuters] 7.6%
8/8 Patient in Sarepta gene therapy trial develops serious illness; shares plunge [Reuters] 7.0%
10/31 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 6.7%
12/12 Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53 6.5%
9/10 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents at Morgan Stanley 17th Annual Global Healthcare Conference (Transcript) [Seeking Alpha] 6.3%
10/4 Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy 6.0%
11/7 Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments 4.9%
6/4 Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference 4.9%
TOP News Decliners
8/19
Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application
-15.0%
3/6 Form 4 Sarepta Therapeutics, For: Mar 04 Filed by: Wigzell Hans Lennart Rudolf -8.6%
10/4 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents Limb-Girdle Muscular Dystrophy Type 2E Functional Results (Transcript) [Seeking Alpha] -8.3%
5/12 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -8.0%
2/26 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments -8.0%
8/21 Pfizer Digs Deeper Into Gene Therapy, Rivaling These Biotech Stocks [Investor's Business Daily] -6.6%
1/22 Sarepta shares fall 4% after FDA documents show safety concern about drug [Reuters] -6.4%
8/7 Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments -5.7%
8/30 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -5.4%
8/8 This Biotech Crashed On 'Erroneous' Report — Plus 2 Stocks That Diverged [Investor's Business Daily] -5.4%
3/6 Form 4 Sarepta Therapeutics, For: Mar 04 Filed by: Wigzell Hans Lennart Rudolf -8.6%
10/4 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents Limb-Girdle Muscular Dystrophy Type 2E Functional Results (Transcript) [Seeking Alpha] -8.3%
5/12 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -8.0%
2/26 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments -8.0%
8/21 Pfizer Digs Deeper Into Gene Therapy, Rivaling These Biotech Stocks [Investor's Business Daily] -6.6%
1/22 Sarepta shares fall 4% after FDA documents show safety concern about drug [Reuters] -6.4%
8/7 Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments -5.7%
8/30 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -5.4%
8/8 This Biotech Crashed On 'Erroneous' Report — Plus 2 Stocks That Diverged [Investor's Business Daily] -5.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: